Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A

Nuclear Medicine and Biology

Volumn 41, Issue 8, 2014, Pages 695-704

  Ooms, Maarten ^a,b   Celen, Sofie ^a,b   Koole, Michel ^c   Langlois, Xavier ^d   Schmidt, Mark ^d   De Angelis, Meri ^d   Andrés, José Ignacio ^d   Verbruggen, Alfons ^a,b   Van Laere, Koen ^b,e   Bormans, Guy ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b KU Leuven   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

11C; CNS imaging; PDE10A; Positron emission tomography

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; 2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE C 11; 2 [[4 [1 (2 FLUOROETHYL) 4 (4 PYRIDINYL) 1H PYRAZOL 3 YL]PHENOXY]METHYL] 5 METHOXYPYRIDINE F 18; CARBON 11; FLUORINE 18; JNJ 42071965; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; TRACER; UNCLASSIFIED DRUG; CARBON; ENZYME INHIBITOR; FLUORINE; PDE10A PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RAT; TISSUE DISTRIBUTION; ANIMAL; BLOOD; BRAIN; DEFICIENCY; DIAGNOSTIC USE; GENE INACTIVATION; GENETICS; METABOLISM; MOUSE; PROCEDURES; SCINTISCANNING; SYNTHESIS;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; CHEMISTRY TECHNIQUES, SYNTHETIC; ENZYME INHIBITORS; FLUORINE RADIOISOTOPES; GENE KNOCKOUT TECHNIQUES; MALE; MICE; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOCHEMISTRY; RATS;

EID: 84922727059     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.05.138     Document Type: Article

References (27)

1. Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 1999, 96:7071-7076.
2. Fujishige K., Kotera J., Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 1999, 266:1118-1127.
3. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., Krull D.L., et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003, 985:113-126.
4. Coskran T.M., Morton D., Menniti F.S., Adamowicz W.O., Kleiman R.J., Ryan A.M., et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006, 54:1205-1213.
5. Hebb A.L.O., Robertson H.A. Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 2007, 7:86-92.
6. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., Chambers L., et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006, 51:386-396.
7. Giampà C., Laurenti D., Anzilotti S., Bernardi G., Menniti F.S., Fusco F.R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010, 5:e13417.
8. Lee C.-M., Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006, 27:310-316.
9. Cunningham V.J., Gunn R.N., Matthews J.C. Quantification in positron emission tomography for research in pharmacology and drug development. Nucl Med Commun 2004, 25:643-646.
10. Celen S., Koole M., De Angelis M., Sannen I., Chitneni S.K., Alcazar J., et al. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 2010, 51:1584-1591.
11. Verhoest P.R., Chapin D.S., Corman M., Fonseca K., Harms J.F., Hou X., et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 2009, 52:5188-5196.
12. Ooms M., Celen S., Verbruggen A., Van Laere K., Bormans G. Synthesis and preliminary biological evaluation of [11C]-MP10 and its regio-isomer as potential radioligands for positron emission tomography imaging of phosphodieasterase-10A in the brain. Eur J Nucl Med Mol Imaging 2010, 37:S206.
13. Tu Z., Fan J., Li S., Jones L.A., Cui J., Padakanti P.K., et al. Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem 2011, 19:1666-1673.
14. Plisson C., Salinas C., Weinzimmer D., Labaree D., Lin S.-F., Ding Y.-S., et al. Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl Med Biol 2011, 38:875-884.
15. Andrés J.-I., De Angelis M., Alcázar J., Iturrino L., Langlois X., Dedeurwaerdere S., et al. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem 2011, 54:5820-5835.
16. Celen S., Koole M., Ooms M., De Angelis M., Sannen I., Cornelis J., et al. Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A. Neuroimage 2013, 82:13-22.
17. Van Laere K., Ahmad R.U., Hudyana H., Dubois K., Schmidt M.E., Celen S., et al. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain. J Nucl Med 2013, 54:1285-1293.
18. Van Laere K., Ahmad R.U., Hudyana H., Celen S., Dubois K., Schmidt M.E., et al. Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur J Nucl Med Mol Imaging 2013, 40:254-261.
19. Plisson C., Weinzimmer D., Jakobsen S., Natesan S., Salinas C., Lin S.-F., et al. Phosphodiesterase 10A PET radioligand development program: from pig to human. J Nucl Med 2014, 55:595-601.
20. Hwang D.-R., Hu E., Rumfelt S., Easwaramoorthy B., Castrillon J., Davis C., et al. Initial characterization of a PDE10A selective positron emission tomography tracer [(11)C]AMG 7980 in non-human primates. Nucl Med Biol 2014, 41:343-349.
21. Fritzberg A.R., Whitney W.P., Kuni C.C., Klingensmith W. Biodistribution and renal excretion of 99mTc-N, N'-bis-(Mercaptoacetamido) ethylenediamine. Effect of renal tubular transport inhibitors. Int J Nucl Med Biol 1982, 9:79-82.
22. Casteels C., Vermaelen P., Nuyts J., Van Der Linden A., Baekelandt V., Mortelmans L., et al. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med 2006, 47:1858-1866.
23. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., Harms J.F., et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008, 325:681-690.
24. Tu Z., Xu J., Jones L.A., Li S., Mach R.H. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol 2010, 37:509-516.
25. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003;5:376-89.
26. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009, 30:431-440.
27. Zoghbi S.S., Shetty H.U., Ichise M., Fujita M., Imaizumi M., Liow J.-S., et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med 2006, 47:520-527.